DiaMedica Therapeutics Inc
$ 6.85
3.47%
17 Apr - close price
- Market Cap 369,095,000 USD
- Current Price $ 6.85
- High / Low $ 7.04 / 6.67
- Stock P/E N/A
- Book Value 1.04
- EPS -0.70
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.68 %
- 52 Week High 10.42
- 52 Week Low 3.34
About
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$15.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2025-11-12 | 2025-08-12 | 2025-05-06 | 2025-03-17 | 2024-11-11 | 2024-08-07 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 | 2023-05-15 |
| Reported EPS | -0.17 | -0.17 | -0.18 | -0.18 | -0.18 | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.16 | -0.2 |
| Estimated EPS | -0.175 | -0.17 | -0.19 | -0.18 | -0.1725 | -0.15 | -0.16 | -0.16 | -0.14 | -0.13 | -0.18 | -0.16 |
| Surprise | 0.005 | 0 | 0.01 | 0 | -0.0075 | 0 | 0.03 | 0.02 | 0 | 0.01 | 0.02 | -0.04 |
| Surprise Percentage | 2.8571% | 0% | 5.2632% | 0% | -4.3478% | 0% | 18.75% | 12.5% | 0% | 7.6923% | 11.1111% | -25% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DMAC
2026-04-14 20:40:06
This article provides the EBITDA per share information for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). The content appears to be a financial data snippet from TradingView, focusing on key financial metrics for the specified biotechnology company.
2026-04-03 11:40:00
HC Wainwright has revised its Q1 2026 EPS forecast for DiaMedica Therapeutics (NASDAQ: DMAC) to ($0.17), an improvement from their previous estimate of ($0.18). The firm also adjusted projected losses across 2026 and 2027, and notably projects profitability of $0.56 per share by FY2030. Despite a significant revenue miss in Q4, the stock holds a "Moderate Buy" consensus rating with a substantial upside to its average price target.
2026-04-02 10:09:21
This article announces an SEC ARS filing by DiaMedica Therapeutics Inc. (DMAC), with a neutral sentiment and low impact. The filing was accepted on April 1, 2026, and provides details about the company's financial overview, recent news, and other SEC filings. DMAC's market capitalization is $349.16 million, and it operates in the biotechnology industry.
2026-04-01 19:40:09
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is proposing to expand its 2019 Omnibus Incentive Plan by adding 3.5 million shares, increasing the total authorized shares to 10.5 million, and extending the plan's term by ten years. This proposal will be voted on at the annual shareholder meeting on May 20, 2026, alongside the election of directors, ratification of Baker Tilly US, LLP as auditors, and an advisory vote on executive compensation. The company states the expansion is crucial for attracting, motivating, and retaining talent and aligns with its pay-for-performance compensation philosophy.
2026-04-01 12:11:16
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) held its Q4 2025 earnings call, highlighting significant progress in its DM199 development programs for preeclampsia and acute ischemic stroke. The company reported positive interim results for preeclampsia, showing DM199's potential as a disease-modifying therapy with no placental barrier crossing, and announced regulatory clearance for a global Phase II trial in Canada. For the stroke program, enrollment for the ReMEDy2 trial is nearing 70% for interim analysis, with an independent safety board recommending continued enrollment. Financial results indicate a cash position of $59.9 million, expected to fund operations through 2027.
2026-04-01 11:40:25
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported a larger operating loss in 2025 due to increased investment in its clinical pipeline, particularly for its DM199 programs. Despite a net loss of $32.766 million, the company maintains a strong cash position of $59.9 million, which it expects will fund operations through the second half of 2027. This financial strategy supports the advancement of its DM199 candidates for preeclampsia, fetal growth restriction, and acute ischemic stroke, including ongoing and planned Phase 2/3 trials.
